MeSH D005770 - gastrointestinal neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D005770:Â
Gastrointestinal neoplasms
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Doxorubicin | Doxorubicin |  | 1995-07-28 |  |  |
| Doxorubicin | Myocet (previously Myocet) |  | 2000-07-13 |  |  | |
| Mylan | Doxorubicin, Doxorubicin hydrochloride | Doxorubicin |  | 2011-10-28 |  |  |
| Roche | Trastuzumab | Herceptin |  | 2000-08-28 | $2,044.082 M | Q4/22-Q3/23 |
| Trastuzumab, Pertuzumab | Phesgo |  | 2020-12-21 | $1,191.313 M | Q4/22-Q3/23 | |
| Pfizer | Doxorubicin | Adriamycin |  | 1991-01-30 |  |  |
| Doxorubicin | Doxorubicin |  | 1982-01-01 |  |  | |
| Trastuzumab | Trazimera |  | 2019-03-11 | $172 M | Q3/22-Q2/23 | |
| Dr Reddys Laboratories | Doxorubicin | Doxorubicin |  | 2017-05-15 |  |  |
| Zydus Therapeutics | Doxorubicin | Doxorubicin |  | 2020-09-10 |  |  |
| Sun Pharmaceutical Industries | Doxorubicin | Doxorubicin |  | 2012-02-15 |  |  |
| Amneal Pharmaceuticals | Doxorubicin | Doxorubicin |  | 2017-02-17 |  |  |
| Bristol Myers Squibb | Doxorubicin | Rubex |  | 1989-04-13 |  |  |
| Accord Healthcare | Trastuzumab | Zercepac |  | 2020-07-27 |  |  |
| Doxorubicin | Zolsketil pegylated |  | 2022-05-31 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
74%37/50
Phase 2
14%10/72
Phase 3
20%5/25
Approved: 4Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use